Boron compound from Anacor prepares for Phase III psoriasis trials
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has reported positive preliminary results from a Phase IIb trial of its phosphodiesterase-4 (PDE4) inhibitor, AN2728, to treat psoriasis, and said the data will help inform the design of Phase III studies for the product.